Tempus Review

Founded 2015, public 2024, 40 million de-identified research records in Lens. That's not a pitch deck number — that's a genuine data moat. Foundation Medicine and Guardant Health compete on genomics, but neither brings multimodal data — genomic, imaging, clinical — plus an AI layer in one stack. The viability question answers itself.

The breadth is real. ECG-AI for cardiology, Tempus PRO Notetaker for neurology and psychiatry, Pixel for radiology imaging, NEXT for clinical trial matching. That's not feature bloat — that's a platform play. The tradeoff: you're buying into a complex, multi-product relationship with no published pricing. Every dollar gets negotiated. Budget cycles will be slower.

Pilot on one disease area — oncology is the strongest anchor. Don't try to standardize across specialties until you see the EHR integration hold up in production.

The 40 million de-identified research records in Tempus Lens is the number that matters. Foundation Medicine sequences well; Guardant Health owns liquid biopsy. Tempus's moat is multimodal breadth — pairing genomic profiling with imaging via Tempus Pixel and structured EHR data. That's a harder architecture to replicate than a single-assay competitor.

From a clinical workflow standpoint, NEXT for trial matching and PurIST® for pancreatic therapy selection show that the AI layer is connected to actual treatment decisions, not research abstraction. ECG-AI and Tempus PRO Notetaker in neurology suggest real specialty expansion, though those capabilities are earlier-stage than the oncology core.

The tradeoff worth naming: contact-only pricing and no published API docs means integration timelines are institutional negotiations, not self-service deployments. If we adopt this, in 3 years our clinical informatics team is deeply coupled to Tempus's data licensing terms — that's a governance conversation before a technology one.

No pricing page. No trial. No published rate card. Every contract starts with a sales call. That's standard for clinical genomics — Foundation Medicine and Guardant Health run the same playbook — but procurement teams should budget 60-90 days to close, minimum. EHR integration is listed as a feature, which means IT onboarding costs are real and not reflected anywhere public.

The platform's 40M de-identified records and features like PurIST® algorithmic testing and Tempus Lens suggest a mature data asset. Genomic profiling, clinical trial matching, and ECG-AI span multiple departments — meaning multi-stakeholder procurement, not a single budget owner. Year 3 TCO at a mid-size health system likely compounds: sequencing contracts, Lens data licensing, NEXT matching, and EHR integration fees are all separate line items.

ROI is measurable in theory — trial enrollment gaps closed, therapy matches made — but the value story depends on internal clinical champions documenting outcomes. Without a published overage structure or contract term norms, budget risk sits with the buyer.

Genomic Profiling with paired tumor/normal and transcriptome sequencing is the core workflow anchor. When a patient's molecular panel comes back, having that result surface alongside matched historical cases and open trial eligibility through NEXT — without leaving the EHR — is genuinely different from what Foundation Medicine offers at the point of care. EHR Integration isn't a checkbox feature here; it's how the whole thing becomes daily habit rather than a separate login.

Day three reality: the PRO™ Notetaker for neurology and psychiatry is a smart add, but specialty teams outside oncology will feel the product is still finding its footing. ECG-AI and Tempus Pixel are promising, but the docs show zero public changelog, zero API documentation. That's a signal. Configuring Lens for a research query or customizing ALGOS outputs likely requires account management, not self-service.

No published pricing is the honest friction. Contrast with Guardant Health, which at least gives test-level cost signals. Budget conversations with administration drag when every number requires a sales call. For academic medical centers with established contracts, that's fine. For smaller oncology practices, it's a real barrier.

Founded in 2015, went public on Nasdaq in 2024, and sitting on what they call the world's largest library of clinical and molecular data — that's not a startup flexing, that's a platform with real weight behind it. The genomic profiling, the PurIST® algorithm for pancreatic cancer therapy selection, the 40 million de-identified research records in Tempus Lens — this is infrastructure-grade stuff. Foundation Medicine and Guardant Health are the named competitors, and Tempus's multimodal angle (genomic plus imaging plus clinical records) is a real differentiator.

The tradeoff is contact-only pricing and a website that tells clinicians almost nothing about what onboarding actually looks like. No docs, no changelog, no pricing page in the evidence. That's a deliberate enterprise sales motion, not a product gap — but it means day-one friction is entirely dependent on your sales rep.

For a working clinician, the EHR integration and Tempus One AI assistant are what decide whether this becomes daily habit or quarterly report. Web-only platform with no free trial means you're committing on faith before you've felt the thing.

Three tells upfront. One: 'world's largest library' in the meta description — the kind of superlative that ages poorly. Two: no API docs, no changelog, no pricing page visible. Three: contact-only sales with zero public tier anchors. All standard for enterprise healthcare, but still flags.

What's actually real: 40 million de-identified records is a specific, meaningful number. The PurIST® algorithm for pancreatic therapy selection, ECG-AI for cardiac screening, Tempus Pixel for radiology — these aren't vaporware feature names, they're named products with clinical use cases. EHR integration matters here. Data without workflow access dies in clinical settings. Tempus Lens for real-world data licensing is where pharma money likely lives.

Exit portability is rough. Genomic data, clinical integrations, proprietary ML models — you don't walk away clean. That's not unique to Tempus; Foundation Medicine and Guardant Health carry the same lock-in. The 2024 IPO buys survival runway. If the data moat holds, it's a real 3-year bet.